Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 602,285 shares, an increase of 289.0% from the June 15th total of 154,817 shares. Based on an average trading volume of 18,970,380 shares, the days-to-cover ratio is presently 0.0 days. Currently, 12.9% of the shares of the company are sold short.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Creative Medical Technology stock. Jane Street Group LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned approximately 1.17% of Creative Medical Technology at the end of the most recent quarter. 1.42% of the stock is currently owned by institutional investors and hedge funds.

Creative Medical Technology Price Performance

Shares of NASDAQ CELZ traded down $0.03 during midday trading on Friday, hitting $0.91. 348,255 shares of the company’s stock were exchanged, compared to its average volume of 10,086,134. The stock’s 50 day moving average price is $1.97 and its 200-day moving average price is $2.00. The firm has a market cap of $4.32 million, a P/E ratio of -0.43 and a beta of 1.89. Creative Medical Technology has a twelve month low of $0.79 and a twelve month high of $6.25.

Creative Medical Technology (NASDAQ:CELZ) last posted its earnings results on Friday, May 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.01. On average, analysts expect that Creative Medical Technology will post -1.14 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a report on Friday, May 22nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce”.

Creative Medical Technology Company Profile

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical?stage biotechnology company focused on the development, manufacture and commercialization of exosome?based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti?inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell?free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.